SuperworthDexCom, Inc. DXCM
Medical - Devices, Healthcare
$84.30
+1.09%
- Market cap
- $31.8B
- PE
- 33.3×
- 10y median 142×
- Forward PE
- Price to sales
- 6.4×
- EV/EBIT
- 27.4×
- Revenue, 12 months
- $5B
- +16% on a year ago
- Net margin
- 20.1%
- Free cash flow yield
- 4.4%
DexCom trades at 33.3× trailing earnings, cheaper than 93% of the last ten years. Revenue was $5B over the last twelve months, up 16% on a year earlier with a 20% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $1B | $921M | $1B | $994.2M | $1.1B+8% | $1B+13% | $1.2B+15% | $1.2B+22% | $1.3B+13% | $1.2B+15% | $1.3B+13% | |
| Cost of revenue | $377.9M | $359.1M | $377.6M | $400.4M | $457.7M+21% | $447M+25% | $468.3M+24% | $477.9M+19% | $466.9M+2% | $441.6M−1% | $478.4M+2% |
| Gross profit | $656.6M | $561.9M | $626.7M | $593.8M | $655.8M−0% | $589M+5% | $688.8M+10% | $731.4M+23% | $792.7M+21% | $750.3M+27% | $830M+21% |
| R&D | $136.1M | $141.5M | $136M | $135.4M | $139.5M+3% | $145.2M+3% | $148.2M+9% | $157.5M+16% | $148.2M+6% | $145.3M+0% | $153M+3% |
| SG&A | $303.6M | $319.3M | $332.7M | $306.4M | $327.4M+8% | $310.1M−3% | $328M−1% | $331.4M+8% | $321.5M−2% | $349.7M+13% | $358.7M+9% |
| $216.9M | $101.1M | $158M | $152M | $188.9M−13% | $133.7M+32% | $212.6M+35% | $242.5M+60% | $323M+71% | $255.3M+91% | $318.3M+50% | |
| Interest expense | $4.9M | $4.6M | $4.8M | $4.7M | $4.9M+0% | $4.7M+2% | $4.7M−2% | $4.7M+0% | $4.2M−14% | $3.1M−34% | $3M−36% |
| Pre-tax income | $246.2M | $132.5M | $187.8M | $177.4M | $211.3M−14% | $154.3M+17% | $241.1M+28% | $352.3M+99% | $340.7M+61% | $269.5M+75% | $317.5M+32% |
| −$10.1M | −$13.9M | $44.3M | $42.8M | $59.6M | $48.9M | $61.3M+38% | $68.5M+60% | $73.4M+23% | $70M+43% | $68.4M+12% | |
| Net income | $256.3M | $146.4M | $143.5M | $134.6M | $151.7M−41% | $105.4M−28% | $179.8M+25% | $283.8M+111% | $267.3M+76% | $199.5M+89% | $249.1M+39% |
| $0.62 | $0.36 | $0.35 | $0.34 | $0.38−39% | $0.27−25% | $0.45+29% | $0.70+106% | $0.68+79% | $0.51+89% | $0.64+42% | |
| 415.9M | 416.7M | 416.8M | 410.2M | 406.7M−2% | 407.5M−2% | 408.2M−2% | 407.4M−1% | 398.9M−2% | 393.6M−3% | 390.1M−4% |
From each company's 10-Q and 10-K filings. Fiscal years are four fiscal quarters added up; balance sheet lines are as of the period's end. Growth is on the same period a year earlier.
Estimates
Next earnings report: .
Analyst consensus for the next eight quarters, with the range from the lowest to the highest estimate, is part of Superworth Pro.
Peers
Companies in Medical - Devices within ten times DexCom's size, closest in size first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| DXCMDexCom, Inc. | $31.8B | 33.3× | 142× | 6.4× | +16% | 20.1% | |
| GEHCGE HealthCare Technologies Inc. | $29.2B | 18.7× | 19.9× | 1.4× | +7% | 9.3% | |
| EWEdwards Lifesciences Corporation | $49.4B | 49.3× | 40.5× | 7.6× | +15% | 15.4% | |
| BSXBoston Scientific Corporation | $60.3B | 16.8× | 66.3× | 2.9× | +14% | 17.5% | |
| SYKStryker Corporation | $105.6B | 28.5× | 41.2× | 4.1× | +8% | 14.4% | |
| MDTMedtronic plc | $109.4B | 21.1× | 28.4× | 2.9× | +10% | 13.9% | |
| ABTAbbott Laboratories | $170.8B | 31.8× | 36.2× | 3.7× | +8% | 11.6% | |
| Peer median | $82.9B | 24.8× | 38.3× | 3.3× | +9% | 14.2% |
About
- Industry
- Medical - Devices
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .